Improving brain organoid models for studying 22q11.2 deletion syndrome
An Engineered Hydrogel Platform to Improve Neural Organoid Reproducibility for a Multi-Organoid Disease Model of 22q11.2 Deletion Syndrome
This study is looking to improve brain organoid models to better understand 22q11.2 deletion syndrome, using a special gel that helps create a more realistic environment for brain growth, which could help researchers learn more about this condition and how it affects development.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11079562 on NIH RePORTER |
What this research studies
This research focuses on enhancing the reliability and reproducibility of brain organoid models to better understand neurodevelopmental disorders, specifically 22q11.2 deletion syndrome. By using a bioengineered hydrogel platform, the study aims to create a more accurate in vitro environment that mimics the natural brain architecture and maturation processes. The researchers will investigate how different biochemical cues and physical properties of the matrix affect the growth and development of these organoids. This innovative approach could lead to significant advancements in studying the mechanisms of neurodevelopment and related disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years diagnosed with 22q11.2 deletion syndrome.
Not a fit: Patients outside the age range of 0-11 years or those without a diagnosis of 22q11.2 deletion syndrome may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for children affected by 22q11.2 deletion syndrome.
How similar studies have performed: While the approach of using engineered hydrogels for organoid culture is innovative, similar methodologies have shown promise in other neurodevelopmental research, indicating potential for success.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Huang, Michelle S — Stanford University
- Study coordinator: Huang, Michelle S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.